These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 26692764)

  • 1. Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer.
    Inoue K; Fry EA
    Genet Epigenet; 2015; 7():19-32. PubMed ID: 26692764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers.
    Olsson E; Honeth G; Bendahl PO; Saal LH; Gruvberger-Saal S; Ringnér M; Vallon-Christersson J; Jönsson G; Holm K; Lövgren K; Fernö M; Grabau D; Borg A; Hegardt C
    BMC Cancer; 2011 Sep; 11():418. PubMed ID: 21957977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational Inferences of the Functions of Alternative/Noncanonical Splice Isoforms Specific to HER2+/ER-/PR- Breast Cancers, a Chromosome 17 C-HPP Study.
    Menon R; Panwar B; Eksi R; Kleer C; Guan Y; Omenn GS
    J Proteome Res; 2015 Sep; 14(9):3519-29. PubMed ID: 26147891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TGF-β1 promotes epithelial-to-mesenchymal transition and stemness of prostate cancer cells by inducing PCBP1 degradation and alternative splicing of CD44.
    Chen Q; Gu M; Cai ZK; Zhao H; Sun SC; Liu C; Zhan M; Chen YB; Wang Z
    Cell Mol Life Sci; 2021 Feb; 78(3):949-962. PubMed ID: 32440711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD44 splice isoform switching determines breast cancer stem cell state.
    Zhang H; Brown RL; Wei Y; Zhao P; Liu S; Liu X; Deng Y; Hu X; Zhang J; Gao XD; Kang Y; Mercurio AM; Goel HL; Cheng C
    Genes Dev; 2019 Feb; 33(3-4):166-179. PubMed ID: 30692202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer.
    Friedrichs K; Franke F; Lisboa BW; Kügler G; Gille I; Terpe HJ; Hölzel F; Maass H; Günthert U
    Cancer Res; 1995 Nov; 55(22):5424-33. PubMed ID: 7585612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion.
    Gaiteiro C; Soares J; Relvas-Santos M; Peixoto A; Ferreira D; Paulo P; Brandão A; Fernandes E; Azevedo R; Palmeira C; Freitas R; Miranda A; Osório H; Prieto J; Lima L; Silva AMN; Santos LL; Ferreira JA
    Theranostics; 2022; 12(7):3150-3177. PubMed ID: 35547758
    [No Abstract]   [Full Text] [Related]  

  • 8. Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer.
    Inoue K; Fry EA
    Int J Cancer; 2016 Jul; 139(1):33-41. PubMed ID: 26802432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD44s and CD44v8-10 isoforms confer acquired resistance to osimertinib by activating the ErbB3/STAT3 signaling pathway.
    Liu YN; Tsai MF; Wu SG; Chang TH; Shih JY
    Life Sci; 2024 Jan; 336():122345. PubMed ID: 38092140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential Biomarkers Associated with Prognosis and Trastuzumab Response in HER2+ Breast Cancer.
    Castro-Guijarro AC; Sanchez AM; Flamini MI
    Cancers (Basel); 2023 Sep; 15(17):. PubMed ID: 37686651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
    Takada M; Higuchi T; Tozuka K; Takei H; Haruta M; Watanabe J; Kasai F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Ogawa S; Kaneko Y
    BMC Cancer; 2013 May; 13():241. PubMed ID: 23679233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
    Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
    Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.
    Martin-Castillo B; Lopez-Bonet E; Cuyàs E; Viñas G; Pernas S; Dorca J; Menendez JA
    Oncotarget; 2015 Oct; 6(32):32317-38. PubMed ID: 26474458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD44: structure, function, and association with the malignant process.
    Naor D; Sionov RV; Ish-Shalom D
    Adv Cancer Res; 1997; 71():241-319. PubMed ID: 9111868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin 7 receptor alpha Thr244Ile genetic polymorphism is associated with susceptibility and prognostic markers in breast cancer subgroups.
    Vitiello GAF; Losi Guembarovski R; Amarante MK; Ceribelli JR; Carmelo ECB; Watanabe MAE
    Cytokine; 2018 Mar; 103():121-126. PubMed ID: 28964592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cell-to-patient machine learning transfer approach uncovers novel basal-like breast cancer prognostic markers amongst alternative splice variants.
    Villemin JP; Lorenzi C; Cabrillac MS; Oldfield A; Ritchie W; Luco RF
    BMC Biol; 2021 Apr; 19(1):70. PubMed ID: 33845831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD44 and its implication in neoplastic diseases.
    Xu Y; Bai Z; Lan T; Fu C; Cheng P
    MedComm (2020); 2024 Jun; 5(6):e554. PubMed ID: 38783892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesenchymal splice isoform of CD44 (CD44s) promotes EMT/invasion and imparts stem-like properties to ovarian cancer cells.
    Bhattacharya R; Mitra T; Ray Chaudhuri S; Roy SS
    J Cell Biochem; 2018 Apr; 119(4):3373-3383. PubMed ID: 29130517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of hormones on CD44 expression in endometrial and breast carcinomas.
    Durst B; Sorg RV; Röder G; Betz B; Beckmann MW; Niederacher D; Bender HG; Dall P
    Oncol Rep; 2001; 8(5):987-93. PubMed ID: 11496303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.